Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

Year in Review: Structural Heart in 2025 Features EARLY TAVR, Tricuspid Nuance, Mitral Gains

Caitlin E. Cox

December 31, 2025

News Daily News

Valve Thrombosis in TTVR Not Uncommon: Meta-analysis

Caitlin E. Cox

June 17, 2025

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Daily News

US and European Valvular Guidelines Mostly Concordant, Analysis Finds

L.A. McKeown

August 21, 2023

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

DOACs Safe, Effective in Subset of Valvular AF Patients

Shelley Wood

March 31, 2021

News Daily News

Bioprosthetic Valve Thrombosis Rare but Not Benign: New Insights

Yael L. Maxwell

February 28, 2020

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

News Conference News EHRA 2019

Thromboembolic Risks High in Patients With A-fib, Valvular Disease

Todd Neale

March 25, 2019

News Opinion Conversations in Cardiology

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

November 16, 2018

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Shelley Wood

August 27, 2017

News Daily News

Anticoagulation in Pregnant Women With Mechanical Heart Valves: A Balancing Act

Caitlin E. Cox

May 31, 2017

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Todd Neale

March 15, 2017

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

News Daily News

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

L.A. McKeown

July 13, 2015

News Industry News

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

June 26, 2015

News Industry News

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

June 22, 2015

Advertisement

Year in Review: Structural Heart in 2025 Features EARLY TAVR, Tricuspid Nuance, Mitral Gains

Valve Thrombosis in TTVR Not Uncommon: Meta-analysis

August 2024 Dispatch for the CV Team

US and European Valvular Guidelines Mostly Concordant, Analysis Finds

Roughly 80% of ESC Guideline Writers Have Financial COIs

DOACs Safe, Effective in Subset of Valvular AF Patients

Bioprosthetic Valve Thrombosis Rare but Not Benign: New Insights

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Thromboembolic Risks High in Patients With A-fib, Valvular Disease

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Anticoagulation in Pregnant Women With Mechanical Heart Valves: A Balancing Act

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content